A controlled trial of riluzole in amyotrophic lateral sclerosis

New England Journal of Medicine

Volumn 330, Issue 9, 1994, Pages 585-591

  Bensimon, G ^a   Lacomblez, L ^a   Meininger, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PLACEBO; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FRACTURE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SPASTICITY; SURVIVAL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RILUZOLE; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT OUTCOME;

EID: 0028097839     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199403033300901     Document Type: Article

References (28)

1. Charcot JM. Lecons sur les maladies du systeme nerveux faites a la Salpetriere. Paris: Progres Medical, 1877:213-42.
2. Jablecki CK, Berry C, Leach J Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989; 12: 833-841
3. Norris FH, Denys EH, Sang K, Mukai E The natural history of ALS in a specified population, with comments on risk factors, prognosis and symptomatic treatments. Clin Neurol 1989; 29: 1485-1492
4. Caroscio JT, Mulvihill MN, Sterling R, Abrams B Amyotrophic lateral sclerosis: its natural history. Neurol Clin 1987; 5: 1-8
5. Kondo K, Hemmi I Clinical statistic in 515 fatal cases of motor neuron disease. Neuroepidemiology 1984; 3: 129-148
6. Bensimon G, Rozier A, Dib M, Lacomblez L, Bouche P, Meininger V Variables influencing the functional loss and the rate of evolution in amyotrophic lateral sclerosis. Neurology 1992; 42: Suppl 3: 202-202 abstract.
7. Rowland LP Ten central themes in a decade of ALS research. Adv Neurol 1991; 56: 3-23
8. Plaitakis A, Caroscio JT Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 575-579
9. Plaitakis A Altered glutamatergic mechanisms and selective motor neuron degeneration in amyotrophic lateral sclerosis: possible role of glycine. Adv Neurol 1991; 56: 319-326
10. Hugon J, Tabaraud F, Rigaud M, Vallat JM, Dumas M Glutamate dehydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease. Neurology 1989; 39: 956-958
11. Rothstein JD, Martin LJ, Kuncl RW Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-1468
12. Plaitakis A, Smith J, Mandeli J, Yahr MD Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1988; 1: 1015-1018
13. Testa D, Caraceni T, Fetoni V Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 1989; 236: 445-447
14. Mizoule J, Meldrum B, Mazadier M, 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission — I. Anticonvulsant properties. Neuropharmacology 1985; 24: 767-773
15. Martin D, Thompson MA, Nadler JV The neuroprotective agent riluzole inhibits release of L-glutamate and L-aspartate from slices of hippocampal area CA1. Br J Pharmacol 1991; 104: Suppl: 240P-240P abstract.
16. CPMP Working Party on Efficacy of Medicinal ProductsEEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990; 67: 361-372
17. Swash M, Leish N Criteria for diagnosis of familial amyotrophic lateral sclerosis: European FALS Collaborative Group. Neuromuscul Disord 1992; 2: 7-9
18. Brooks BR, Sufit RL, DePaul R, Tan YD, Sanjak M, Robbins J Design of clinical therapeutic trials in amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 521-546
19. Rozier A, Lacomblez L, Chatelier G, Bensimon G, Bouche P, Meininger V Interrater reliability of a new rating scale for amyotrophic lateral sclerosis. J Neurol Sci 1990; 98: Suppl: 316-316 abstract.
20. Lacomblez L, Bouche P, Bensimon G, Meininger V A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635-1637
21. Freedman LS Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1: 121-129
22. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170
23. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
24. Wu MC, Carroll RJ Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 1988; 44: 175-188
25. Durrleman S, Alperovitch A Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989; 39: 768-773
26. Peto R. Statistical aspects of cancer trials. In: Halnan KE, ed. Treatment of cancer. London: Chapman & Hall, 1982:868-71.
27. Benoit E, Escande D Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 1991; 419: 603-609
28. Doble A, Hubert JP, Blanchard JC Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992; 140: 251-254